These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9718050)

  • 1. Lipid-lowering therapy after myocardial infarction: the Bavarian Cholesterol Screening Project.
    Richter WO; Schwandt P
    JAMA; 1998 Aug; 280(7):603-4. PubMed ID: 9718050
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: Lipid-lowering drugs after myocardial infarction.
    Lancet; 1975 Mar; 1(7905):501-2. PubMed ID: 46964
    [No Abstract]   [Full Text] [Related]  

  • 3. Secondary prevention of coronary disease with lipid-lowering drugs.
    Lancet; 1989 Mar; 1(8636):473-4. PubMed ID: 2563844
    [No Abstract]   [Full Text] [Related]  

  • 4. Gemfibrozil to prevent myocardial infarction.
    Rembold CM
    Ann Intern Med; 1998 Nov; 129(9):750. PubMed ID: 9841617
    [No Abstract]   [Full Text] [Related]  

  • 5. Increasing prescription of drugs for secondary prevention of myocardial infarction. Lipid lowering drugs should be considered too.
    Taylor A; Reckless JP
    BMJ; 1996 Jan; 312(7025):252. PubMed ID: 8563613
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of lipid lowering on coronary plaques and coronary events.
    Roberts WC
    Am J Cardiol; 1997 Oct; 80(8B):8H-9H. PubMed ID: 9372992
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of intensive lipid lowering on coronary atheroma and clinical outcome.
    Houslay ES; Sarma J; Uren NG
    Heart; 2007 Feb; 93(2):149-51. PubMed ID: 17035507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The importance of determining the type of hyperlipidemia for lipotropic therapy of atherosclerosis].
    Bavina MV; Perova NV; Lobova NM; Koropova GI
    Kardiologiia; 1973 Mar; 13(3):27-33. PubMed ID: 4717180
    [No Abstract]   [Full Text] [Related]  

  • 9. Testing the efficacy of lipid-lowering therapy versus revascularization: the time has come, or is it past due?
    Enas EA
    Circulation; 1998 Jun; 97(25):2584-6. PubMed ID: 9657483
    [No Abstract]   [Full Text] [Related]  

  • 10. A case for lipid lowering? Response to Dr Paul Durrington.
    Yudkin JS
    Diabet Med; 2001 May; Suppl 3():11-2. PubMed ID: 11534306
    [No Abstract]   [Full Text] [Related]  

  • 11. Prescribing of lipid regulating drugs and admissions for myocardial infarction in England.
    Majeed A; Aylin P; Williams S; Bottle A; Jarman B
    BMJ; 2004 Sep; 329(7467):645. PubMed ID: 15374914
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipoprotein(a) measurement and determining risk of myocardial infarction.
    Jones SR; Blumenthal RS
    JAMA; 2009 Oct; 302(15):1645; author reply 1645-6. PubMed ID: 19843896
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence of new atherothrombotic brain infarction in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol >or=125 mg/dl treated with statins versus no lipid-lowering drug.
    Aronow WS; Ahn C; Gutstein H
    J Gerontol A Biol Sci Med Sci; 2002 May; 57(5):M333-5. PubMed ID: 11983729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cholesterol controversy.
    Rybinski EA
    BMJ; 1992 Mar; 304(6828):712. PubMed ID: 1571654
    [No Abstract]   [Full Text] [Related]  

  • 15. Improving lipid control following myocardial infarction.
    Ankam J; Feldman DI; Blaha MJ; Martin SS
    Curr Opin Cardiol; 2014 Sep; 29(5):454-66. PubMed ID: 25046003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hyperlipidaemia as a risk factor for coronary heart disease: the role of fibrates.
    Linssen R
    Hosp Med; 1999 Apr; 60(4):298-301. PubMed ID: 10396439
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of lipid-lowering medication in patients with acute myocardial infarction (Worcester Heart Attack Study).
    Goldberg RJ; Ockene IS; Yarzebski J; Savageau J; Gore JM
    Am J Cardiol; 1997 Apr; 79(8):1095-7. PubMed ID: 9114770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of HMG Co-A reductase inhibitors following acute myocardial infarction in hospital practice.
    Khong TK; Missouris CG; Murda'h M; MacGregor GA
    Postgrad Med J; 1998 Oct; 74(876):600-1. PubMed ID: 10211353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ALLHAT trial: strengths and limitations.
    Fagard RH
    J Hypertens; 2003 Feb; 21(2):229-32. PubMed ID: 12569242
    [No Abstract]   [Full Text] [Related]  

  • 20. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
    Burgess DC; Hunt D; Li L; Zannino D; Williamson E; Davis TM; Laakso M; Kesäniemi YA; Zhang J; Sy RW; Lehto S; Mann S; Keech AC
    Eur Heart J; 2010 Jan; 31(1):92-9. PubMed ID: 19797259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.